Open Access iconOpen Access

REVIEW

crossmark

The roles and mechanisms of miRNA in HBV-HCC carcinogenesis: Why no therapeutic agents after 30 years?

KURT SARTORIUS1,2,3,*, BENN SARTORIUS4, CHERIE WINKLER5, ANIL CHUTURGOON2, ANNA KRAMVIS1, PING AN5, WEIGANG ZHANG6, YUNJIE LU3,6,7,*

1 Hepatitis Diversity Research Unit, School of Internal Medicine, University of the Witwatersrand, Johannesburg, 2050, South Africa
2 School of Laboratory Medicine and Molecular Sciences, University of KwaZulu-Natal, Durban, 4041, South Africa
3 Africa HepatoPancreatoBiliary Cancer Consortium (AHPBCC), Mayo Clinic, Jacksonville, MN 55902, USA
4 Centre for Clinical Research (UQCCR), Faculty of Medicine, University of Queensland, Brisbane, NSW2580, Australia
5 Basic Research Laboratory, Centre for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Inc., Frederick Nat. Lab. for Cancer Research, Frederick, MD 240, USA
6 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215100, China
7 Department of General Surgery, Wujin Hospital Affiliated with Jiangsu University, Zhenjiang, 212013, China

* Corresponding Authors: KURT SARTORIUS. Email: email; YUNJIE LU. Email: email

TSP_BIOCELL_55505.pdf

  • 420

    View

  • 121

    Download

  • 0

    Like

Share Link